MiR-491-5p, as a Tumor Suppressor, Prevents Migration and Invasion of Breast Cancer by Targeting ZNF-703 to Regulate AKT/mTOR Pathway

References

• Pakiž M, Lukman L, Kozar N. Patients’ and physicians’ expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer. Eur J Gynaecol Oncol. 2019;40(5):781–786.
   Web of Science ®Google Scholar
• Watkins EJ. Overview of breast cancer. JAAPA. 2019;32(10):13–17. doi:10.1097/01.JAA.0000580524.95733.3d
   PubMedGoogle Scholar
• Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2020;65:18–31. doi:10.1016/j.bpobgyn.2019.11.00631862315
   PubMed Web of Science ®Google Scholar
• Rossi L, Mazzara C, Pagani O. Diagnosis and treatment of breast cancer in young women. Curr Treat Options Oncol. 2019;20(12):86. doi:10.1007/s11864-019-0685-731776799
   PubMed Web of Science ®Google Scholar
• Slepicka PF, Cyrill SL, Dos Santos CO. Pregnancy and breast cancer: pathways to understand risk and prevention. Trends Mol Med. 2019;25(10):866–881. doi:10.1016/j.molmed.2019.06.00331383623
   PubMed Web of Science ®Google Scholar
• Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51(4):759–774. doi:10.1177/030098581350282024045890
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207. doi:10.1016/j.jaci.2017.08.03429074454
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465. doi:10.1002/jcp.2748630471116
   PubMed Web of Science ®Google Scholar
• Fridrichova I, Zmetakova I. MicroRNAs contribute to breast cancer invasiveness. Cells. 2019;8(11):1361. doi:10.3390/cells8111361
   PubMed Web of Science ®Google Scholar
• Rahman MM, Brane AC, Tollefsbol TO. MicroRNAs and epigenetics strategies to reverse breast cancer. Cells. 2019;8(10):1214. doi:10.3390/cells8101214
   PubMed Web of Science ®Google Scholar
• Loh HY, Norman BP, Lai KS, Rahman N, Alitheen NBM, Osman MA. The regulatory role of MicroRNAs in breast cancer. Int J Mol Sci. 2019;20(19):4940. doi:10.3390/ijms20194940
   PubMed Web of Science ®Google Scholar
• Daoud AZ, Mulholland EJ, Cole G, McCarthy HO. MicroRNAs in pancreatic cancer: biomarkers, prognostic, and therapeutic modulators. BMC Cancer. 2019;19(1):1130. doi:10.1186/s12885-019-6284-y31752758
   PubMed Web of Science ®Google Scholar
• Boca S, Gulei D, Zimta AA, et al. Nanoscale delivery systems for microRNAs in cancer therapy. Cell Mol Life Sci. 2020;77(6):1059–1086.31637450
   PubMed Web of Science ®Google Scholar
• Liu F, Zhang H, Xie F, et al. Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis. Oncogene. 2020;39(8):1696–1709. doi:10.1038/s41388-019-1092-z31705065
   PubMed Web of Science ®Google Scholar
• Qi G, Li L. LncRNA TTN-AS1 promotes progression of non-small cell lung cancer via regulating miR-491-5p/ZNF503 axis. Onco Targets Ther. 2020;13:6361–6371. doi:10.2147/OTT.S23889032669856
   PubMed Web of Science ®Google Scholar
• Ren P, Hong X, Chang L, Xing L, Zhang H. USF1-induced overexpression of long noncoding RNA WDFY3-AS2 promotes lung adenocarcinoma progression via targeting miR-491-5p/ZNF703 axis. Mol Carcinog. 2020;59(8):875–885. doi:10.1002/mc.2318132275336
   PubMed Web of Science ®Google Scholar
• Xiao S, Xu N, Ding Q, Huang S, Zha Y, Zhu H. LncRNA VPS9D1-AS1 promotes cell proliferation in acute lymphoblastic leukemia through modulating GPX1 expression by miR-491-5p and miR-214-3p evasion. Biosci Rep. 2020;40(10). doi:10.1042/BSR20193461
   Web of Science ®Google Scholar
• Xu G, Zhang Y, Li N, et al. LBX2-AS1 up-regulated by NFIC boosts cell proliferation, migration and invasion in gastric cancer through targeting miR-491-5p/ZNF703. Cancer Cell Int. 2020;20(1):136. doi:10.1186/s12935-020-01207-w32351330
   PubMed Web of Science ®Google Scholar
• Wörmann B. Breast cancer: basics, screening, diagnostics and treatment. Med Monatsschr Pharm. 2017;40(2):55–64.29952495
   PubMedGoogle Scholar
• Bushati N, Cohen SM. MicroRNA functions. Annu Rev Cell Dev Biol. 2007;23(1):175–205. doi:10.1146/annurev.cellbio.23.090506.12340617506695
   PubMed Web of Science ®Google Scholar
• Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35(1):3–11. doi:10.1055/s-0034-139734425632930
   PubMed Web of Science ®Google Scholar
• Laity JH, Lee BM, Wright PE. Zinc finger proteins: new insights into structural and functional diversity. Curr Opin Struct Biol. 2001;11(1):39–46. doi:10.1016/S0959-440X(00)00167-611179890
   PubMed Web of Science ®Google Scholar
• Chiu H-W, Chen C-H, Chang J-N, Chen C-H, Hsu Y-H. Far-infrared promotes burn wound healing by suppressing NLRP3 inflammasome caused by enhanced autophagy. J Mol Med. 2016;94(7):809–819. doi:10.1007/s00109-016-1389-026864306
   PubMed Web of Science ®Google Scholar
• Squassina A, Meloni A, Chillotti C, Pisanu C. Zinc finger proteins in psychiatric disorders and response to psychotropic medications. Psychiatr Genet. 2019;29(5):132–141. doi:10.1097/YPG.000000000000023131464994
   PubMed Web of Science ®Google Scholar
• Sircoulomb F, Nicolas N, Ferrari A, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med. 2011;3(3):153–166. doi:10.1002/emmm.20110012121328542
   PubMed Web of Science ®Google Scholar
• Orhan C, Bakır B, Dalay N, Buyru N. ZNF703 is an important player in head and neck cancer. Clin Otolaryngol. 2019;44(6):1080–1086. doi:10.1111/coa.1345031574205
   PubMed Web of Science ®Google Scholar
• Baykara O, Dalay N, Kaynak K, Buyru N. ZNF703 overexpression may act as an oncogene in non-small cell lung cancer. Cancer Med. 2016;5(10):2873–2878. doi:10.1002/cam4.84727650486
   PubMed Web of Science ®Google Scholar
• Yang G, Ma F, Zhong M, et al. ZNF703 acts as an oncogene that promotes progression in gastric cancer. Oncol Rep. 2014;31(4):1877–1882. doi:10.3892/or.2014.299724481460
   PubMed Web of Science ®Google Scholar
• Ma F, Bi L, Yang G, et al. ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer. Oncol Rep. 2014;32(3):1071–1077. doi:10.3892/or.2014.331325017610
   PubMed Web of Science ®Google Scholar
• Yang H, Jiang WQ, Cao Y, et al. Elevated ZNF703 protein expression is an independent unfavorable prognostic factor for survival of the patients with head and neck squamous cell carcinoma. Dis Markers. 2015;2015:640263. doi:10.1155/2015/64026326063961
   PubMed Web of Science ®Google Scholar
• Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–189. doi:10.1007/82_2017_628550454
   PubMed Web of Science ®Google Scholar
• Ghoneum A, Said N. PI3K-AKT-mTOR and NFκB pathways in ovarian cancer: implications for targeted therapeutics. Cancers (Basel). 2019;11(7):949. doi:10.3390/cancers11070949
   PubMed Web of Science ®Google Scholar
• Rahmani F, Ziaeemehr A, Shahidsales S, et al. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J Cell Physiol. 2020;235(5):4146–4152. doi:10.1002/jcp.2933331663122
   PubMed Web of Science ®Google Scholar
• Sharma V, Sharma AK, Punj V, Priya P. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: a focus on breast cancer. Semin Cancer Biol. 2019;59:133–146. doi:10.1016/j.semcancer.2019.08.00531408722
   PubMed Web of Science ®Google Scholar